Generic and Specialty Pharmaceuticals (TRBC)

China`s Fosun, Shanghai Pharma say bid for stake in U.S. drugmaker Arbor

China`s Fosun, Shanghai Pharma say bid for stake in U.S. drugmaker Arbor

Published 14/08/2017

A unit of China's Fosun Group and Shanghai Pharmaceuticals Holding Co (601607.SS) are among bidders for a stake in U.S. speciality drugmaker Arbor Pharmaceuticals LLC, the companies said on Monday. [more…]

AstraZeneca gets breakthrough status for blood cancer drug

AstraZeneca gets breakthrough status for blood cancer drug

Published 01/08/2017

FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014.

AstraZeneca said on Tuesday that U.S. regulators had awarded its blood cancer drug acalabrutinib "breakthrough" status for the treatment of patients with mantle cell lymphoma, a rare type of blood cancer.

[more…]

Express Scripts to cover Mylan`s EpiPen, exclude rivals

Express Scripts to cover Mylan`s EpiPen, exclude rivals

Published 31/07/2017

EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016.

Pharmacy benefit manager Express Scripts Holding Co said on Monday it would favor drugmaker Mylan Inc's versions of the EpiPen lifesaving allergy treatment over the allergy auto-injectors of other companies.

[more…]

Eaton Vance fund managers see major upside for healthcare stocks: Barron`s

Eaton Vance fund managers see major upside for healthcare stocks: Barron`s

Published 16/07/2017

The portfolio managers of the $1.2 billion Eaton Vance Worldwide Health Sciences fund are expecting big gains from a trio of healthcare stocks.

[more…]

Morphosys sees revenue boost from Janssen psoriasis drug

Morphosys sees revenue boost from Janssen psoriasis drug

Published 14/07/2017

German biotech group Morphosys expects to receive royalties from psoriasis drug guselkumab for five months this year, its Chief Executive Simon Moroney said, after its licensee received U.S. regulatory approval.

[more…]

Financials get European shares off to firm start- payday for Carillion shorts

Financials get European shares off to firm start- payday for Carillion shorts

Published 10/07/2017

Traders work in front of the German share price index, DAX board, at the stock exchange in Frankfurt, Germany, July 4, 2017. REUTERS/Staff/Remote

European stocks edged higher on Monday, with banks and utilities the strongest sectors, as mergers and acquisitions rumbled on with some broker notes also prompting individual stock moves.

[more…]

Roche, Shire court fight underscores high stakes in hemophilia

Roche, Shire court fight underscores high stakes in hemophilia

Published 10/07/2017

FILE PHOTO: Swiss drugmaker Roche's logo is seen at their headquarters in Basel, Switzerland January 28, 2016. REUTERS/Arnd Wiegmann/File Photo

Roche's bid to muscle in on Shire's share of the $11 billion hemophilia drug market took a new, contentious turn this weekend when the British drugmaker won a court injunction against how the Swiss drugmaker talks about its new medicine.

[more…]

Shire gets injunction against Roche over hemophilia drug

Shire gets injunction against Roche over hemophilia drug

Published 09/07/2017

CEO of Shire, Dr Flemming Ornskov, poses for a photograph in London, Britain, July 3, 2017. REUTERS/Peter Nicholls - RTS19MDH

Pharmaceutical group Shire (SHP.L) said on Sunday it had obtained a preliminary injunction in a Hamburg court against rival Roche (ROG.S) over its hemophilia drug emicizumab, alleging incomplete and misleading statements surrounding the treatment.

[more…]

Lupin sets off down Indian pharma`s long road to redemption

Lupin sets off down Indian pharma`s long road to redemption

Published 09/07/2017

An employee inspects tablets as they move along the production line at a pharmaceutical plant of Lupin, India's No. 2 drugmaker, in Verna, in the western state of Goa, India, June 9, 2017. Picture taken June 9, 2017. REUTERS/Danish Siddiqui

In 28 years in India's pharmaceuticals sector, Rajiv Desai has never been busier.

[more…]

Inotek to explore strategic options after eye drug fails trial

Inotek to explore strategic options after eye drug fails trial

Published 07/07/2017

Inotek Pharmaceuticals Corp said on Friday it would evaluate strategic options after its sole experimental eye drug failed another trial, sending the company's shares tumbling 45 percent in extended trading.

[more…]